Statera Biopharma and Immune Therapeutics Inc. Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone. Potential indication payments will include asthma, multiple sclerosis, HIV and chemotherapy. In aggregate, this transaction has the ability to generate over $400 million in non-dilutive payments to Statera.
Biotech
$BTTXBetter Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
IBB Biotech reversal pattern after bounce from TL; low may be inIBB bounced from the green pandemic support zone last March but have came back down to retest this zone.
IBB has found support exactly on my GANN FAN line for several times before it breaks down & retested the violet downtrend line & bounced, making a reversal with a long hammer candle.
IBB may close today above my GANN FAN line support confirming reversal . Closing the next few days above 124 the pre-pandemic high would give added confidence to the bottom reversal pattern.
Next resistances are 127 & 136 to make a higher high.
Not trading advice
$BCTX poised to bounce $BCTX - BriaCell is a cancer treatment biotech that recently dropped 40% AFTER receiving fast track designation for FDA approval. The drop was somewhat coincidental as it's month long bull run finished with a FinTwit pump and dump. BUT the retrace is in and it's approaching historical trend lines and levels of support and looks poised to bounce in the coming week. TD9 is flashing a buy signal, but I wouldn't be shocked if it begins to curl throughout the week. Looking to enter a long swing trade to ride it back to previous highs.
GOVX Corporate Update soon | 10X Upside Potential Analyst RatingGOVX GeoVax Labs is a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer.
GeoVax Labs will report Q1 2022 financial results on April 27.
Jason McCarthy from Maxim Group has a $10.00 price target for GOVX.
The stock is now $1.01.
Market Cap of only 7.23Mil.
This is a 4X upside potential short term stock in my opinion.
BIOFRONTERA Looking for that 55-75% GainLooking Long, seeking bullish PA around buy zone. Looking to execute on a share dealing account, stop loss is kept in mind.
MSFT: Sell Zone is 325-330MSFT is finishing up its 4th wave pullback. Mega caps don't typically experience deep retracements, so the .382 retracement is the perfect buying zone. In the next day or two MSFT will resume its uptrend to complete its 5th wave up to the $325-$330 region. After that, MSFT will experience a 2nd wave pullback to approximately today's levels.
$SRRA Long term PTs 79-145 and higher...Parabolic! (HCW)Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
$PFE Key Levels, Analysis, & Targets $PFE Key Levels, Analysis, & Targets
Swing setup
1 at 47.59
1 at 45.65
2 at 41.06
4 at 38.36
8 at 34.40
(Then multiply by your multiplier (x5, x10, x100, x1000, etc to find your position size)
Looking for 15%, up to 20% if all targets hit…
---
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed.
GL and happy trading.
IF you need anything analyzed Technically just comment with the Ticker and I’ll do it as soon as possible…
Battered biotech. Sorrento therapeutics is a chart that interests me. Measured move from pennant hit exactly which explains the bounce but I am anticipating a move down to horizontal support at 1.50.
Will go into more detail on the daily chart.
RSI flashed into oversold conditions recently however no bullish divergence.
High risk high reward however any buys in this area, in the past has paid off well.
Very volatile swings.
NRXP all time low! 2 X Phase 3 clinical trials! NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.
52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.
My price target is 16.50
If this is not the time to buy this stock, then when?!
TECH BIO-TECHNE PREDICTIONI believe that TECH is bearish after evaluating MACD on the 35 and 45-minute charts.
NTLA Intellia Therapeutics Inc. BPC Chart Overview 03/28/22Intellia Therapeutics Inc. NASDAQ: NTLA
Chart Overview 03/28/22
Intellia is trading in a 9-month downward channel pullback, closing the gap created by the release of Phase 1 data of NTLA-2001 to treat ATTR. The release caused a bull pennant that led to a reversal into a downward channel. We are tracking support at $56 and a resistance line is at $90. The downward channel pullback may be forming a descending wedge, which could lead to a bullish breakout.
Tracking RSI and MACD, the lowest lows on both charts are displaying a slight increase, running opposite to price, which lowest lows are continuing to decrease. The bullish divergence also indicates a possible breakout if met with an increase in volume. Good news could mean that the recent bottom is in, possible clinical holds, or other issues could test 2021 lows around $44. We will be looking for a breakout over $90 into a new bullish pattern.
Intellia will be commencing Part 2 of its NTLA-2001 and is set to read out from its Phase 1/2 NTLA-2002 hereditary angioedema (HAE) trial this year. A recent loss in a CRISPR patent ruling increases uncertainty in the stock. Catalysts can have a profound effect on stock price and incorporating BioPharmCatalyst into your due diligence can ensure that you are prepared.
Track 1000+ catalysts and access over 800+ companies’ fundamentals, earnings and analyst ratings by becoming a BPC Premium Subscriber. Sign up for your FREE trial at www.biopharmcatalyst.com
Get a daily breakdown of biotech investor news straight to your inbox with our pre and post market newsletters sign up here www.biopharmcatalyst.com
BCTX BriaCell Therapeutics Corp: BPC Chart Overview 03/28/22BriaCell Therapeutics Corp. NASDAQ: BCTX
Chart Overview 03/28/22
BriaCell broke out of a 3-month downward channel into an upward channel. We are tracking support lines at $4.20, $5, and $5.89, and resistance lines at $9.60 and $10.47. Friday and today shares are trading overextended and coming up to resistance both in terms of channel lines, candlesticks, resistance price at $6.90. Shares are currently trading above the 1st resistance at $9.60, and we will be watching changes in volume to confirm the breakout.
Through utilizing the Stochlistics chart, it appears that the price is overbought and a possible indicator of a return to the pattern. If the channel holds then we will look to retest the $6.90 resistance to see if it breaks out and moves higher into new recent highs.
Track 1000+ catalysts and access over 800+ companies’ fundamentals, earnings and analyst ratings by becoming a BPC Premium Subscriber. Sign up for your FREE trial at www.biopharmcatalyst.com
Get a daily breakdown of biotech investor news straight to your inbox with our pre and post market newsletters sign up here www.biopharmcatalyst.com
BCEL Ripe for a PopIf you look at this chart, definitely looks like BCEL is ripe for a pop. The blue line I have on there would be where I'd start thinking about selling, probably 5 cents less than that and it's going down hill.
Elevation Oncologys personalised treatment plans for cancer ⚕️I find that the cash ($146M) vs valuation (55M) is rocket fuel for “the herd”. Also presenting itself as an “undiscovered gem” may contribute to a good ol’ pop.
They have good social media skills and their website is gorgeous. Being that this will be about as much DD as the masses ever do it can and most times is quite important for fueling said pop.
RSI in the low lows lends a little more to the “undiscovered gem” ideology even though I loath technical analysis many do not.
News about their phase II study (which they seem to be taking very seriously) should come to light within the following months and as any biotech investor knows: news + biotech = insane short term gains.
Check out my ideas on Utradea
Miromatrix and their bioengineered pig-human hybrid organs 🐷The set up for a pump seems to be falling nicely into place, cheap, small cap, descent into oblivion, interesting tech, “undiscovered gem” feeling.
The volume is dastardly and it could still fall sub $2 before making a comeback.
They may pull a card out of their sleeve tomorrow at CareDx’s Xenotransplantation Innovation Day however it seems unlikely. It is probably a better idea to wait for news on the initiation of the phase I trials for their external liver assist program. Around that time if there is an uptick in social media buzz we may very well be in for a good ol’ pump, probably followed by an offering to fill the coffers if the stock price gains permit.
Long The High Risk Psilocybin Mushroom Therapy Secular Bull RunNot looking for an immediate turn around because Macro-Market conditions and retail risk tolerance is severely negative right now. However, this sector has huge potential to be a bullish meme in years ahead. Think of getting into Pot Stocks 2.0 before the moon pumps
In 2018–19, the United States Food and Drug Administration (FDA) granted breakthrough therapy designation to facilitate further research for psilocybin in the possible treatment of depressive disorders. As of 2020, research on the use of psilocybin indicated it caused hallucinations with inability to establish reality from fantasy, panic reactions, and possible psychoses at high doses.
In November 2020, the U.S. state of Oregon legalized psilocybin for people age 21 and older, and decriminalized possession or use of psilocybin mushrooms for medical conditions, such as depression, anxiety, or PTSD.
Allarity priming itself for a pumpAs with most micro biotech companies, I expect the price to continue to fall to the $1 region and then “flatten out” for a while to keep its head just above the minimum listing requirement. It will then probably remain there until it is seemingly forgotten.
Then, in a move to regain compliance (if it falls below $1) we can expect some financial reorganisation on the stocks behalf and possibly a R/S on the cards if things get dire.
If it remains over the minimum listing price, I expect some group of pumpers to catch on to Allarity and we could see a few weeks of growing buzz on social media platforms, followed by some handy articles and a sudden parabolic move upwards on news as FOMO kicks in to the herd.
$AMGN LONG IDEA$AMGN is one of my favorite bio tech stocks as it has solidified its place as a winner over the years. They had a bit of a slowdown and consolidation over the past few years as they didn't have as much involvement with COVID, but certainly didn't lose too much value.
Watch for a 4hr close above $241.50 to send us back to $260+ over next few weeks.
Biotechnology is the next sector to have big runnersI'm looking at Biotechnologies and healthcare sector for my next sector that is going to run beyond the oil industry. Oil is going to die down in the next week or two because the Biden admin will want that to go hush hush. I estimate we will still have one or two more really rallies in the oil industry before we see the whole sector of biotech go nuts. Again just a prediction. I'm broker than the next guy in stocks so follow me if you want to run into crazy stuff.
BCEL is my pick as a great potential for the sector move. It has volume, a low float and looks like it's setting up for crossing over the 200 ma. I don't really like to make those trades before they cross over the 200ma because they haven't officially broken the trend until they are over the 200 ma and sustain it, but BCEL may be a good short term play.
$XBI Monthly approaching buy zoneStarted XBI LEAPS position buying JAN 24 $150 Calls, will continue to add as XBI Biotech has taken a beating, but technically has just found it's way back to the long term upward trendline support zone.
First price target 120, followed by 140 after expecting a bit more downside here.
This is a long term trade idea, for those looking in the short term, there may still be more downside although the R/R favors the long position now IMO.
$XBI Key Levels, Analysis & Targets - Request$XBI Key Levels, Analysis & Targets - Request
Ok, @FlashingGraphs so these would be my targets fo XBI. It sounds like you don’t have an open position yet… I would start around 78.06.
Then if it keeps selling off, then double your position at 62.94
And if it still continues then double again at 45.89. If those 3 hit then you can expect a solid 50% swing from there…
Because of the way the Biotech sector moved in the past two years I could definitely see it making a 3 standard deviation move down like this, in correction. Don’t go in too heavy until you see a clear reversal sign… (such as macD crossing back above 0, and consistent higher lows)
And with that being said I still would start building from Target 1. I hope this helps.
GL & happy swinging…
